
The FDA approves durvalumab for bladder cancer and gefurulimab for myasthenia gravis, creating distinct ADC, biologic, and autoinjector production needs.
Study focused on demonstrating the effect of freeze-thaw of conjugated critical reagents on the binding capacity in immunogenicity assay performance.






